While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?
Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia
Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Is the FDA Too Cautious? | Open to Debate podcast - Listen or read transcript on Metacast
